Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Martin

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
JCO Oncology Practice|May 21, 2025
Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United StatesKelly E McCann, Virginia Kaklamani, Noran Osman, et al.
The Journal of Trauma|June 11, 2009
What are we missing: results of a 13-month active follow-up program at a level I trauma centerAjai K Malhotra, Nancy Martin, Melanie Jacoby, et al.
The Journal of Trauma|October 14, 2008
Predictive value of broncho-alveolar lavage fluid Gram's stain in the diagnosis of ventilator-associated pneumonia: a prospective studyAaron E Goldberg, Ajai K Malhotra, Omer J Riaz, et al.
Breast Cancer Research and Treatment|March 6, 2025
Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence studyKelly E McCann, Noran Osman, Joan Cannon, et al.
Urology|June 18, 2013
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladderSender Herschorn, Jack Barkin, David Castro-Diaz, et al.
Frontiers in Neurology|February 24, 2016
A Prospective Pilot Investigation of Brain Volume, White Matter Hyperintensities, and Hemorrhagic Lesions after Mild Traumatic Brain InjuryMichael Jarrett, Roger Tam, Enedino Hernández-Torres, et al.
Molecular and Cellular Biology|December 16, 2015
C/EBPγ Is a Critical Regulator of Cellular Stress Response Networks through Heterodimerization with ATF4Christopher J Huggins, Manasi K Mayekar, Nancy Martin, et al.
Molecular and Cellular Biology|June 19, 2013
C/EBPγ suppresses senescence and inflammatory gene expression by heterodimerizing with C/EBPβChristopher J Huggins, Radek Malik, Sook Lee, et al.
The Journal of Clinical Endocrinology and Metabolism|February 3, 2023
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCTKimball A Johnson, Nancy Martin, Rossella E Nappi, et al.
Cancers|November 13, 2021
The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT ActivityYuan-Yin Chen, Rebecca Dagg, Yuchen Zhang, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
JCO Oncology Practice|May 21, 2025
Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United StatesKelly E McCann, Virginia Kaklamani, Noran Osman, et al.
The Journal of Trauma|June 11, 2009
What are we missing: results of a 13-month active follow-up program at a level I trauma centerAjai K Malhotra, Nancy Martin, Melanie Jacoby, et al.
The Journal of Trauma|October 14, 2008
Predictive value of broncho-alveolar lavage fluid Gram's stain in the diagnosis of ventilator-associated pneumonia: a prospective studyAaron E Goldberg, Ajai K Malhotra, Omer J Riaz, et al.
Breast Cancer Research and Treatment|March 6, 2025
Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence studyKelly E McCann, Noran Osman, Joan Cannon, et al.
Urology|June 18, 2013
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladderSender Herschorn, Jack Barkin, David Castro-Diaz, et al.
Frontiers in Neurology|February 24, 2016
A Prospective Pilot Investigation of Brain Volume, White Matter Hyperintensities, and Hemorrhagic Lesions after Mild Traumatic Brain InjuryMichael Jarrett, Roger Tam, Enedino Hernández-Torres, et al.
Molecular and Cellular Biology|December 16, 2015
C/EBPγ Is a Critical Regulator of Cellular Stress Response Networks through Heterodimerization with ATF4Christopher J Huggins, Manasi K Mayekar, Nancy Martin, et al.
Molecular and Cellular Biology|June 19, 2013
C/EBPγ suppresses senescence and inflammatory gene expression by heterodimerizing with C/EBPβChristopher J Huggins, Radek Malik, Sook Lee, et al.
The Journal of Clinical Endocrinology and Metabolism|February 3, 2023
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCTKimball A Johnson, Nancy Martin, Rossella E Nappi, et al.
Cancers|November 13, 2021
The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT ActivityYuan-Yin Chen, Rebecca Dagg, Yuchen Zhang, et al.
Pageof 4